The partnership is expected to help customers gain efficiencies, improve the quality standard, boost speed to market, lower total cost of ownership and reduce supply chain risk
Gerresheimer AG Headquarters at Airport City, Duesseldorf. (Credit: Gerresheimer from Wikipedia)
German manufacturing company Gerresheimer and Stevanato Group, drug containment, drug delivery and diagnostic solutions provider, have jointly developed a high-end Ready-To-Use (RTU) solution platform for the pharmaceutical sector.
The new RTU platform is based on the Stevanato Group’s market-leading EZ-fill technology and will be used initially to produce vials.
This partnership is expected to help customers gain efficiencies, improve the quality standard, boost speed to market, lower ownership costs and reduce supply chain risk.
Through the collaboration, Gerresheimer and Stevanato Group seek to make RTU vials a standard for many pharma companies.
Other market participants will have access to the new system to standardise fill-finish operations from the early stages of drug development to commercialisation.
The new platform will share the same secondary packaging, production process, and sterilisation method for consistent capacity availability and reliable double sourcing for the pharmaceutical sector.
It can also improve the quality and performance of RTU solutions by a significant reduction in particles.
Stevanato Group chief business officer Mauro Stocchi said: “Our EZ-fill vial platform is the market’s most established choice for pre-sterilised containers, and this enhanced version for RTU vials will bring to the market its full potential in terms of quality, flexibility and value for Pharmaceutical Companies and CMOs.
“Through our collaboration with Gerresheimer AG we are responding to market demand, and we expect to achieve another important milestone in creating a reliable ecosystem to support, accelerate and de-risk the conversion from bulk to EZ-fill vials already underway in the market.”
The companies plan to present the vial platform and trademark to the market at the CPhI Worldwide Frankfurt in November 2022.